Table 4.
Tumor size at study inclusion correlated with the median overall survival in the three study cohorts
| Tumor size (cm) | Number of cases | Median OS [months] | (95% CI) | P (log rank) | |
|---|---|---|---|---|---|
| All pts | ≤ 5 | 18 | 9.4 | (0.00–20.21) | 0.031 |
| > 5 | 20 | 5.0 | (2.92–7.079) | ||
| ITT | ≤ 5 | 14 | 12.2 | (9.45–14.95) | 0.005 |
| > 5 | 15 | 5.8 | (0.00–11.66) | ||
| PP | ≤ 5 | 7 | 13.4 | (9.55–17.25) | 0.022 |
| > 5 | 13 | 6.9 | (2.79–11.01) |
Significance P < 0.05
ITT (intent-to-treat): all patients treated > 6 weeks, PP (per protocol): patients with dose reduction due to adverse events are excluded, OS: overall survival, 95% CI: 95% confidence interval